Becton Dickinson and Co

Abbott Laboratories beat quarterly profit estimates on Thursday, driven by a rebound in its non-COVID-19 testing business and sales of its medical devices as vaccinations encouraged Americans to resume non-urgent procedures.

A molecular test from Becton Dickinson that detects viruses that cause COVID-19 as well as influenza and produces result in 2-3 hours has been given emergency user authorization by the U.S. health regulator, the company said on Friday.

The U.S. Food and Drug Administration has granted emergency use authorization to a molecular test from Becton Dickinson that can detect viruses that cause COVID-19 as well as influenza and produce results in 2-3 hours, the company said on Friday.

Becton Dickinson on Thursday raised its 2021 profit forecast as the medical device maker expects strong demand for its COVID-19 testing kits to extend into the first half of the year.

Medical technology company Becton Dickinson and Co on Thursday reported a 309% surge in first-quarter profit, fueled by strong demand for its COVID-19 diagnostic tests.

The U.S. government's effort to squeeze more doses from Pfizer Inc's COVID-19 vaccine vials is spurring unanticipated demand for specialized syringes that the world's largest syringe supplier says exceeds existing capacity.

Becton Dickinson and Co on Tuesday forecast first-quarter revenue above Wall Street estimates due to strong demand for its COVID-19 diagnostic tests.

Becton Dickinson and Co will invest about $1.2 billion to boost syringe production, the world's largest needle maker said on Wednesday, as the United States inches closer to making a COVID-19 vaccine available to its people.

Tesla Inc <TSLA.O> Chief Executive Officer Elon Musk questioned the accuracy of COVID-19 tests on Thursday after claiming that results showed he tested positive twice and then negative twice all on the same day.

* BECTON DICKINSON SAYS AWARE OF THE TWEET BY ELON MUSK AND ARE REACHING OUT TO LEARN MORE, CONSISTENT WITH OUR QUALITY MANAGEMENT PROCESS - TWEET

Medical device maker Becton Dickinson and Co <BDX.N> said on Thursday it expects as much as $1.5 billion in sales from its COVID-19 diagnostic test next year, after reporting a quarterly profit that beat Wall Street estimates.

Becton Dickinson and Co on Thursday posted a 16% fall in fourth-quarter profit, as the medical technology company was hurt by patients deferring discretionary procedures due to the COVID-19 pandemic.

Nevada's recent ban on the use of Quidel Corp's Sofia and Becton Dickinson and Co's Veritor point-of-care antigen tests for COVID-19 in long-term care facilities violates federal law, a U.S. government official said on Friday.

U.S. state of Nevada's recent ban on the use of Quidel Corp's Sofia and Becton Dickinson and Co's (BD) Veritor point of care antigen tests in long-term care facilities violates federal law, a U.S. government official said on Friday.

U.S. medical device maker Becton Dickinson and Co said on Wednesday its COVID-19 antigen test kit met the requirements for a launch in Europe.

Becton Dickinson and Co agreed to pay $60 million to resolve allegations by the attorneys general of 48 U.S. states and Washington D.C. that its CR Bard unit concealed the risks of its now-discontinued transvaginal pelvic mesh devices.

Becton Dickinson and Co said on Thursday it has reached a $60 million settlement with the attorneys general of 48 U.S. states and Washington, D.C. to settle litigation related to discontinued pelvic mesh products.

Becton Dickinson and Co said on Thursday it has reached a $60 million settlement with the attorneys general of 48 U.S. states and Washington, D.C. to settle litigation related to discontinued pelvic mesh products.

New York's attorney general on Thursday filed a lawsuit accusing Becton Dickinson and Co's CR Bard unit of concealing the risks of surgical mesh devices.